CDNA

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock. The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniver.

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's relative performance in the quarter were Vishay Precision Group, Babcock & Wilcox, and CareDx (not held). The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.

During the quarter, we initiated a position in Jersey Mike's Subs Inc., a franchisor of fast casual, submarine-style sandwich restaurants. We participated in the IPO of Lyntris Inc., a fast-growing proprietary defense solutions provider with a 90% sole-sourced portfolio exposed to many of the nation's key defense offerings. We sold our position in Wingstop Inc. during the quarter to allocate the proceeds into other restaurant companies where we felt there was better upside potential.

CDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.

CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue of $139 million, an increase of 39% year-over-year Testing Services revenue of $119 million, an increase of 65% year-over-year Testing Services volume of approximately 75,900, an increase of 51% year-ove.

CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.